Laurus Labs Ltd - 540222 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nagarani Chava Laurus Labs Ltd - 540222 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for NSN Holdings Laurus Labs Ltd - 540222 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for NSN Holdings Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings call transcript for Q2 FY 2021-22 for the call held on October 29, 2021
Laurus Labs: New growth levers taking shape
The businesses to track for Laurus Labs, as far as future growth trajectory is concerned, are that of synthesis and biotech
Earnings Call for Q2FY22 of Laurus Labs
Conference Call with Laurus Labs Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript. Laurus Labs Ltd - 540222 - Fixes Record Date for Interim Dividend
Laurus Labs Ltd has informed BSE that the Company has fixed November 18, 2021 as the Record Date for the purpose of Payment of Interim Dividend.The Dividend amount will be paid on or after November 25, 2021.
Q2FY22 Quarterly Result Announced for Laurus Labs Ltd.
Healthy Growth momentum with 17% revenue growth for H1FY22 Q2 FY22 Highlight: Total net revenue Rs. 1,203 crs, up 6 % (Y-o-Y) EBITDA Rs. 348 crs, decreased by 8 % (Y-o-Y) EBITDA margins at 29 % PAT at Rs. 202 crs, decreased by 17 % (Y-o-Y) PAT margins at 17 % (Y-o-Y) EPS (Diluted) for the period at Rs. 3.7 per share (not annualised), decreased by 18 % (Y-o-Y) Declared Interim dividend of Rs. 0.80 /- per share (face value of Rs. 2/-) H1 FY22 Highlights: Revenue at Rs. 2,482 crs, up 17 % (Y-o-Y) EBITDA Rs. 748 crs, up 13 % (Y-o-Y) EBITDA margins at 30 % PAT at Rs. 443 crs, up 7 % (Y-o-Y) PAT margins at 18 % EPS (Diluted)(face value of Rs. 2/-) for the period at Rs. 8.2 per share (not annualised), up by 6% (Y-o-Y) Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “The financial performance of the quarter has been tepid and driven by sales growth. While our profits growth had been modest for the quarter, we clocked heathy growth for H1 FY22. We continue to sharpen our execution across our core business despite challenging times. Our sustained traction in FDF and CDMO business was key driver of the growth. We are focusing on positioning our businesses for sustainable long term growth. Importantly, I am pleased to share that recently our Laurus Synthesis Pvt Ltd (LSPL) unit has executed a multi-year partnership deal with a leading Global Life science company. The deal entails complete drug development and manufacturing of a portfolio of niche APIs. Under the agreement, LSPL will set up a dedicated manufacturing facility to manufacture and supply APIs. We believe the deal demonstrates our technological capabilities and will mark a significant step forward in our evolution as a valuable partner to the global pharmaceutical industry. We are seeing multiple opportunities from several new and existing customers who are looking to diversify and de-risk their existing supply chain.” Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said; “While our Q2 results are slightly subdued we achieved healthy momentum for overall H1 FY22. Laurus Labs reported a modest revenue growth of 6% at Rs. 1,203 crs in Q2FY22, due to transient impact of channel de-stocking for ARV business. EBITDA has declined by 8 % to Rs. 348 crs while our EBITDA margins were maintained. In the 1HFY22, our Revenues have grown 17% to Rs. 2,482 crs, driven by strong momentum in FDF and CDMO business. EBITDA has grown by 13 % to Rs. 748 crs and our Margins have sustained over 30%. Our growth accelerators remains on track supported by much needed strategic investments.” Result PDF Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for Q2 FY 22 Financial Results